National Stroke Foundation

Excedrin Migraine

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1998

Specific Treatments:

Mild-to-moderate migraine

Therapeutic Areas

General Information

Bristol-Myers Squibb received approval of its Excedrin Migraine for the treatment of pain associated with mild-to-moderate migraine. It is the first over the counter drug to be approved for this indication.

Clinical Results

In trials involving about 1300 migraineurs, Excedrin Migraine was found safe and effective in relieving migraine pain within 2-to-4 hours of dosing.

Mechanism of Action

Excedrin Migraine contains 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine in each tablet. The ingredients are the same as those in Excedrin Extra, which is already on the market, but the product comes with instructions and warnings specific to migraine.